- Home
- HSCS vs RDHL Comparison
HSCS vs RDHL Comparison
Compare HSCS & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HSCS
- RDHL
- Stock Information
- Founded
- HSCS 2007
- RDHL 2009
- Country
- HSCS United States
- RDHL Israel
- Employees
- HSCS N/A
- RDHL N/A
- Industry
- HSCS Medical Specialities
- RDHL Biotechnology: Pharmaceutical Preparations
- Sector
- HSCS Health Care
- RDHL Health Care
- Exchange
- HSCS Nasdaq
- RDHL Nasdaq
- Market Cap
- HSCS 3.7M
- RDHL 3.8M
- IPO Year
- HSCS 2022
- RDHL N/A
- Fundamental
- Price
- HSCS $3.57
- RDHL $2.03
- Analyst Decision
- HSCS Strong Buy
- RDHL
- Analyst Count
- HSCS 2
- RDHL 0
- Target Price
- HSCS $13.00
- RDHL N/A
- AVG Volume (30 Days)
- HSCS 50.6K
- RDHL 19.2K
- Earning Date
- HSCS 07-28-2025
- RDHL 04-10-2025
- Dividend Yield
- HSCS N/A
- RDHL N/A
- EPS Growth
- HSCS N/A
- RDHL N/A
- EPS
- HSCS N/A
- RDHL N/A
- Revenue
- HSCS N/A
- RDHL $8,042,999.00
- Revenue This Year
- HSCS N/A
- RDHL $381.91
- Revenue Next Year
- HSCS N/A
- RDHL N/A
- P/E Ratio
- HSCS N/A
- RDHL N/A
- Revenue Growth
- HSCS 261.17
- RDHL 23.17
- 52 Week Low
- HSCS $2.36
- RDHL $1.71
- 52 Week High
- HSCS $5.30
- RDHL $20.28
- Technical
- Relative Strength Index (RSI)
- HSCS 46.34
- RDHL 57.04
- Support Level
- HSCS $3.63
- RDHL $1.75
- Resistance Level
- HSCS $3.92
- RDHL $2.08
- Average True Range (ATR)
- HSCS 0.31
- RDHL 0.09
- MACD
- HSCS -0.02
- RDHL 0.03
- Stochastic Oscillator
- HSCS 8.75
- RDHL 85.16
About HSCS Heart Test Laboratories Inc.
HeartSciences Inc is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. Its objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. It is developing a suite of AI-ECG diagnostic solutions for use in any healthcare care setting, either via MyoVista Insights cloud-platform using one of the millions of ECG devices currently in clinical use or via MyoVista wavECG Device.
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.